ArticleTherapeutic advances in medical oncology2026
Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sacituzumab govitecan (SG), an anti-Trop-2 antibody-drug conjugate (ADC), was approved for metastatic triple-negative breast cancer (mTNBC) with ⩾1 prior therapy and hormone receptor-positive (HoR+) breast cancer progressing on cyclin-dependent kinase 4/6 inhibitor and chemotherapy. However, little real-world evidence is available in China, and the potential predictive biomarker of SG has not been fully investigated. Objectives: Our study aimed to evaluate the effectiveness, safety, and biomarker of SG in Chinese metastatic breast cancer (MBC) patients. Design: A total of 165 MBC patients treated with SG between June 2023 and December 2024 in 4 institutions nationwide were included in this study. SG was administered intravenously at a dosage of 10 mg/kg on days 1 and 8 of a 21-day treatment cycle. Methods: Demographic and clinical data were retrospectively collected and analyzed. Clinical outcomes included real-world progression-free survival (rwPFS), overall survival (OS), objective response rate (ORR), disease control rate, and toxicity. Results: In 103 mTNBC patients, median rwPFS was 5.1 months (95% confidence interval (CI): 3.8-7.4) and median rwOS was 19.7 months (95% CI: 17.3-not reached); in 62 HoR+HER2- patients, median rwPFS was 5.8 months (95% CI: 4.7-7.9), and OS data were immature. Prior PD-1/PD-L1 inhibitors exposure in TNBC showed significantly shorter rwPFS ( Conclusion: In conclusion, SG showed similar effectiveness with ASCENT and TROPiCS-02 study in heavily pretreated Chinese MBC patients. Given the compromised effectiveness in patients with prior PD-1/PD-L1 inhibitors or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.